Back to results
US 8,278,279 B2Granted
Method for treating prostatitis utilizing modified pore-forming protein proaerolysin
AssigneeProtox Therapeutics, Inc.
InventorJ. Curtis Nickel
Life of this patent
Estimating the term…
Abstract
The present disclosure includes methods and compositions for treating any condition involving prostatitis and similar diseases and/or conditions. These methods and compositions involve the use of targeted modified pore-forming proteins, including variant proaerolysin proteins.
Claims20
A method of treating prostatitis in a subject, comprising administering to said subject a therapeutically effective amount of PRX302,
- wherein the PRX302 comprises:
- an amino acid sequence having greater than 98% sequence identity to the amino acid sequence shown in SEQ ID NO:4 and which maintains the ability to selectively target and kill normal prostate cells, and
- an affinity tag.
A method of treating prostatitis in a subject, comprising administering to said subject a therapeutically effective amount of PRX302,
- wherein the PRX302 comprises:
- an amino acid sequence having greater than 98% sequence identity to the amino acid sequence shown in SEQ ID NO:4 and which maintains the ability to selectively target and kill normal prostate cells, and
- a C-terminal polyhistidine tag that includes six histidine residues.
Dependencies are inferred from the claim text.